- Home
- DAIO vs BOLD Comparison
DAIO vs BOLD Comparison
Compare DAIO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAIO
- BOLD
- Stock Information
- Founded
- DAIO 1969
- BOLD 2018
- Country
- DAIO United States
- BOLD United States
- Employees
- DAIO N/A
- BOLD N/A
- Industry
- DAIO Electrical Products
- BOLD
- Sector
- DAIO Industrials
- BOLD
- Exchange
- DAIO Nasdaq
- BOLD Nasdaq
- Market Cap
- DAIO 31.5M
- BOLD 25.5M
- IPO Year
- DAIO N/A
- BOLD 2024
- Fundamental
- Price
- DAIO $3.31
- BOLD $1.28
- Analyst Decision
- DAIO Strong Buy
- BOLD Buy
- Analyst Count
- DAIO 1
- BOLD 4
- Target Price
- DAIO $5.22
- BOLD $4.00
- AVG Volume (30 Days)
- DAIO 21.1K
- BOLD 138.5K
- Earning Date
- DAIO 10-23-2025
- BOLD 11-06-2025
- Dividend Yield
- DAIO N/A
- BOLD N/A
- EPS Growth
- DAIO N/A
- BOLD N/A
- EPS
- DAIO N/A
- BOLD N/A
- Revenue
- DAIO $22,732,000.00
- BOLD N/A
- Revenue This Year
- DAIO $11.25
- BOLD N/A
- Revenue Next Year
- DAIO $5.88
- BOLD N/A
- P/E Ratio
- DAIO N/A
- BOLD N/A
- Revenue Growth
- DAIO N/A
- BOLD N/A
- 52 Week Low
- DAIO $1.88
- BOLD $1.00
- 52 Week High
- DAIO $3.57
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- DAIO 51.40
- BOLD 71.19
- Support Level
- DAIO $3.25
- BOLD $1.10
- Resistance Level
- DAIO $3.42
- BOLD $1.34
- Average True Range (ATR)
- DAIO 0.09
- BOLD 0.05
- MACD
- DAIO -0.01
- BOLD 0.01
- Stochastic Oscillator
- DAIO 41.98
- BOLD 79.17
About DAIO Data I/O Corporation
Data I/O Corp is a provider of programming, security deployment, security provisioning, and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices, and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in the United States, Europe, and Asia and others. The company derives the majority of its revenue from Asia and others.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.